Barclays PLC started coverage on shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) in a research report issued on Wednesday, Marketbeat reports. The firm set an “equal weight” rating and a $60.00 price target on the biopharmaceutical company’s stock. Barclays PLC’s price objective suggests a potential upside of 20.10% from the stock’s previous close.

Several other equities analysts also recently issued reports on the stock. Zacks Investment Research downgraded shares of Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th. Stifel Nicolaus reaffirmed a “buy” rating and set a $111.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Friday, June 30th. Cowen and Company reaffirmed an “outperform” rating on shares of Ultragenyx Pharmaceutical in a report on Thursday, June 29th. ValuEngine raised shares of Ultragenyx Pharmaceutical from a “strong sell” rating to a “sell” rating in a report on Friday, June 2nd. Finally, BidaskClub raised shares of Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating in a report on Tuesday, July 25th. One equities research analyst has rated the stock with a sell rating, twelve have issued a hold rating and eight have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $74.00.

Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) traded down 0.08% during mid-day trading on Wednesday, reaching $49.96. 291,919 shares of the company’s stock traded hands. The company’s market cap is $2.12 billion. Ultragenyx Pharmaceutical has a 12-month low of $49.56 and a 12-month high of $91.35. The company’s 50 day moving average is $59.95 and its 200 day moving average is $64.74.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported ($1.72) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.73) by $0.01. During the same quarter last year, the business posted ($1.46) EPS. On average, analysts predict that Ultragenyx Pharmaceutical will post ($7.21) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/09/10/ultragenyx-pharmaceutical-inc-rare-coverage-initiated-at-barclays-plc.html.

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis purchased 7,500 shares of the firm’s stock in a transaction dated Monday, August 28th. The shares were purchased at an average cost of $52.52 per share, with a total value of $393,900.00. Following the completion of the purchase, the chief executive officer now owns 430,569 shares in the company, valued at approximately $22,613,483.88. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 9.20% of the company’s stock.

Several large investors have recently bought and sold shares of RARE. Fortaleza Asset Management Inc. raised its stake in Ultragenyx Pharmaceutical by 148.5% during the first quarter. Fortaleza Asset Management Inc. now owns 1,640 shares of the biopharmaceutical company’s stock worth $111,000 after purchasing an additional 980 shares during the period. Sei Investments Co. purchased a new position in Ultragenyx Pharmaceutical during the second quarter worth about $125,000. Pacer Advisors Inc. raised its stake in Ultragenyx Pharmaceutical by 22.6% during the first quarter. Pacer Advisors Inc. now owns 3,037 shares of the biopharmaceutical company’s stock worth $206,000 after purchasing an additional 560 shares during the period. Strs Ohio raised its stake in Ultragenyx Pharmaceutical by 10.7% during the first quarter. Strs Ohio now owns 3,100 shares of the biopharmaceutical company’s stock worth $210,000 after purchasing an additional 300 shares during the period. Finally, Tocqueville Asset Management L.P. raised its stake in Ultragenyx Pharmaceutical by 8.0% during the second quarter. Tocqueville Asset Management L.P. now owns 3,375 shares of the biopharmaceutical company’s stock worth $210,000 after purchasing an additional 250 shares during the period. 96.18% of the stock is currently owned by hedge funds and other institutional investors.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.